by Raynovich Rod | Feb 5, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Biotech Bull Market Intact But Technicals Rule On January 27 we reiterated our model for life science stocks for 2014. We will review each component of our model and where the sector stands after about a 5% correction off highs with the sector still up 6% YTD...
by Raynovich Rod | Jan 21, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Stocks Moving Again-XBI up 1.54% After a 15%+ move January YTD you would think it is time to step back and take some off. Today the rally was in a full bull MOde with biopharmaceutical stocks leading the way. Here are big upside movers among our focus...
by Raynovich Rod | Jan 20, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
2014 J.P.Morgan Healthcare Conference Update #4-Rayno Biopharmaceutical Picks Biotechnology started off with a roar and major indices were up 10% or more. Much of it can be attributed to the excitement and anticipation of the JPMorgan Conference with 10,000 attendees...
by Raynovich Rod | Jan 10, 2014 | 2024 Rayno Biopharmaceuticals Portfolio
Biotech Bull Market Enters The Bubblet Phase in Early 2014 (Published in Seeking Alpha on January 9) Buyers Anticipating J.P. Morgan Conference: IBB up 3.79% YTD Last week we started a series of articles that will follow key technical and fundamental trends in the...
by Raynovich Rod | Jan 7, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals
Update 1/8/13 Blow-Off anticipating J.P.Morgan Conference? Breakthrough: IBB hit new highs above $230 today. Green screen with most large cap and mid caps. ALKS, BIIB among movers. XBI is also up 2%. Rayno Life Science stocks are in the bullish groove as investors...
by Raynovich Rod | Dec 24, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Rayno Life Science Stock Picks Beat The Market Everybody now knows about the bull market in biotech stocks. Innovative products, favorable clinical news, M&A (see below) and breakthrough genomic technologies and targeted therapies have driven most life science...
by Raynovich Rod | Dec 19, 2013 | 2023-24 Life Science Portfolios, Macro
Taper Lite With Zero Interest Rates The big FED Meeting with the Bernanke farewell concluded with “taper lite”, optimism on the economy and continued low inflation. The FED decision to roll back its economic stimulus was welcomed by investors boosting the...
by Raynovich Rod | Dec 12, 2013 | Biopharmaceuticals
Biotech Bull Market Takes A Breather When the biotech bull market began in Q2 2009 it was value driven because of low technology values and Price/Sales for the widely covered stocks. Product sales were about to explode for many companies and in 2012 the sector took...
by Raynovich Rod | Dec 9, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Weak Tape Today 12/10–Gilead (GILD) Down 4.4% on 15.5M Shares IBB ($218.81) down 1.33% on good volume. GILD fall could be reaction to Abbvie (ABBV $53.55) up 4.5% on Phase 3 Hepatitis C data. Virologic response of ABT-450r is 96% in Genotype 1 patients. Other...
by Raynovich Rod | Nov 4, 2013 | 2024 Rayno Biopharmaceuticals Portfolio
Updated 2/11/15 see chart below Rayno 2013 Picks Outperform Biotechnology Indices and Funds Biopharmaceutical stocks hit all time highs in 2013 with major ETFs up as follows YTD: FBT ($65) up 41%, IBB ($206) up 50%, and XBI ((%120) up 36%. The Five Star Fidelity...